NCT01800071View on ClinicalTrials.gov

A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 10, 2017

Study Completion Date

March 10, 2017

Conditions
Nasopharyngeal CancerEpstein Barr Virus Infections
Interventions
DRUG

MVA-EBNA1/LMP2 vaccine

Trial Locations (5)

B15 2TT

University of Birmingham, Edgbaston

SW3 6JJ

Royal Marsden Hospital, Fulham Road

CF14 2TL

Velindre Cancer Centre, Cardiff

G12 0YN

The Beatson West of Scotland Cancer, Glasgow

M20 4BX

The Christie Hospital, Manchester

Sponsors

Lead Sponsor

Cancer Research UK
All Listed Sponsors
lead

Cancer Research UK

OTHER

NCT01800071 - A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter